Monthly Meeting
Local Seminars
The Nucleus
Contact Us
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Medicinal Chemistry Group
Our Mission
The mission of the medicinal chemistry group is to advance knowledge and understanding of drug discovery research by organizing world class quality symposia.
Our meetings provide our attendees with access to top quality science presenters and offer unique networking connectivity with thought leaders in the scientific community.
Our members work at the forefront of the life science sector and are constantly striving to bring new medicines and therapies forward to the clinic to meet unmet need.

Volunteer Opportunities
The Medicinal chemistry group will be interested in volunteers to assist with annual symposium specifically for contacting potential vendors and fund-raising efforts. Please contact the med chem chair, Raj Rajur at rrajur@creagenbio.com, if interested.

Who are we?
     
   
  Dr. Raj (SB) Rajur, Chair
  rrajur@creagenbio.com
   
 
   
  Mark Ashwell
  Nimbus Therapeutics
mashwellmail@gmail.com
   
   
  Daniel Elbaum
  Retrophin
ddelbaum@msn.com
   
 
   
  Andrew Scholte
  Sanofi
Andrew.Scholte@genzyme.com
   
   
  Jeremy Green
  Vertex
jeremy_green@vrtx.com
   
 
   
  Blaise Lippa
  Morphic Therapeutic
Blaise.Lippa@morphictx.com
   
   
  Adrian Hobson
  Abbvie
   
 
   
  Brian Aquila
  Alkermes
  BrianAquila@alkermes.com
 
   
  Scott Edmondson
   
   
 
   
  Paul Greenspan
   
   
 
   
  Min Lu
  Merck
  min.lu1@merck.com
 
 
   
  Lisa Marcaurelle
   
   
   
  Kap-Sun Yeung
  Bristol-Meyers Squibb
  KapSun.Yeung@bms.com
 
   

 
WEBINAR
“CoREST Complex-selective HDAC inhibitors promote pro-synaptic effects and represent the potential for promising new therapies to treat synaptopathies”
By Nathan Fuller, Alkermes
Organized by the Medicinal Chemistry Section
of the Northeastern Section, American Chemical Society (NESACS)
 
Thursday – December 10th, 2020
4.00 pm
Register for the November Webinar meeting here:
https://american-chemical-society.zoom.com/webinar/register/WN_SWjA9uAERNyvWc0zsU1EqQ
Download flyer ...
SPEAKER
Nathan Fuller
Director of Chemistry, Alkermes
 
Bio: Nathan received his Ph.D. from the University of North Carolina at Chapel Hill under the guidance of James Morken working on reductive aldol chemistry and its application to total synthesis of natural products.  He then went on to conduct post-doctoral research in the lab of Stephen F. Martin at the University of Texas at Austin on the synthesis of alkaloid natural products.  He began his career as a medicinal chemist at Wyeth Research in Cambridge, MA working in the inflammation group, and then joined Satori Pharmaceuticals in Cambridge, MA where he worked on a program targeting gamma-secretase modulators for the treatment of Alzheimer’s disease.  In 2013, Nathan began a role at AstraZeneca in Waltham, MA in the Chemistry Innovation Centre, working in the Fragment-Based Lead Generation group.  In this role, he worked on a wide range of target classes and therapeutic areas across the AstraZeneca portfolio.  In late 2015, Nathan joined the team at Rodin Therapeutics to lead their chemistry efforts to apply HDAC inhibitors to the treatment of synaptic pathology in neurologic disorders.  In November of 2019, Rodin Therapeutics was acquired by Alkermes, and Nathan has joined the team at Alkermes to continue to advance the science around novel complex-selective HDAC inhibitors.
 
Abstract: Synaptic dysfunction is a pathological feature in many neurodegenerative disorders, including Alzheimer’s disease, and synaptic loss correlates closely with cognitive decline.  Histone deacetylase enzymes (HDACs) are involved in chromatin remodeling and gene expression and have been shown to regulate synaptogenesis and synaptic plasticity, thus providing an attractive drug discovery target for promoting synaptic growth and function.  HDAC1 and HDAC2 associate with multiple co-repressor complexes including CoREST, which regulates the expression of many neuronal genes.  We have identified a series of novel HDAC inhibitor compounds that selectively inhibit the HDAC-CoREST complex, resulting in increases in dendritic spine density and synaptic proteins, and improved long term potentiation in a mouse model at doses which provide a substantial safety margin that would enable chronic treatment.  This approach represents the potential for promising new therapeutic strategies in targeting synaptic pathology involved in multiple neurologic disorders.
 
Symposium Organizing Committee: Brian Aquila, Mark Ashwell, Scott Edmondson, Dan Elbaum, Jeremy Green, Paul Greenspan, Adrian Hobson, Blaise Lippa, Lisa Marcaurelle, Min Lu, Kap-Sun Yeung, Andrew Scholte, Raj (SB) Rajur (Chair)